相似文献
1
Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2).
Eur J Hum Genet. 2010 Sep;18(9). doi: 10.1038/ejhg.2009.232. Epub 2010 Jan 27.
2
Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012.
Eur J Hum Genet. 2013 Jan;21(1). doi: 10.1038/ejhg.2012.164. Epub 2012 Aug 15.
3
Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
Fam Cancer. 2009;8(4):421-9. doi: 10.1007/s10689-009-9258-4. Epub 2009 Jun 13.
4
Evaluation and management of Lynch syndrome.
Clin Adv Hematol Oncol. 2007 Nov;5(11):851,873.
5
Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel.
Am J Surg Pathol. 2009 Nov;33(11):1639-45. doi: 10.1097/PAS.0b013e3181b15aa2.
6
Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
Cancer Res. 2009 Sep 1;69(17):7053-61. doi: 10.1158/0008-5472.CAN-09-0358. Epub 2009 Aug 18.
7
Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome.
Fam Cancer. 2009;8(4):501-4. doi: 10.1007/s10689-009-9276-2. Epub 2009 Aug 12.
8
Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome.
Acta Oncol. 2007;46(6):763-9. doi: 10.1080/02841860701230217.
9
Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC).
Genes Chromosomes Cancer. 2005 Oct;44(2):123-38. doi: 10.1002/gcc.20219.
10
Mismatch repair gene deficiency and genetic anticipation in Lynch syndrome: myth or reality?
Dis Colon Rectum. 2015 Jan;58(1):141-2. doi: 10.1097/DCR.0000000000000275.
引用本文的文献
1
A Rare Variant as a Candidate Marker for Lynch Syndrome II Screening in Tunisia: A Case of Diffuse Gastric Carcinoma.
Genes (Basel). 2022 Jul 28;13(8):1355. doi: 10.3390/genes13081355.
2
Unique Combination of Diamond-Blackfan Anemia and Lynch Syndrome in Adult Female: A Case Report.
Front Oncol. 2021 Apr 16;11:652696. doi: 10.3389/fonc.2021.652696. eCollection 2021.
3
Patient compliance based on genetic medicine: a literature review.
J Community Genet. 2014 Jan;5(1):31-48. doi: 10.1007/s12687-013-0160-2. Epub 2013 Aug 10.
4
The challenge of implementing genetic tests with clinical utility while avoiding unsound applications.
J Community Genet. 2014 Jan;5(1):7-12. doi: 10.1007/s12687-012-0121-1. Epub 2012 Oct 9.
5
Clinical utility gene card for: familial adenomatous polyposis (FAP) and attenuated FAP (AFAP).
Eur J Hum Genet. 2011 Jul;19(7). doi: 10.1038/ejhg.2011.7. Epub 2011 Feb 2.
本文引用的文献
1
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.
Gastroenterology. 2009 Nov;137(5):1621-7. doi: 10.1053/j.gastro.2009.07.039. Epub 2009 Jul 18.
2
Genetic testing in gastroenterology: Lynch syndrome.
Best Pract Res Clin Gastroenterol. 2009;23(2):185-96. doi: 10.1016/j.bpg.2009.02.006.
3
Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
Fam Cancer. 2007;6(3):301-10. doi: 10.1007/s10689-007-9124-1. Epub 2007 Apr 24.
4
Prognostic value of Y deletion analysis: what is the clinical prognostic value of Y chromosome microdeletion analysis?
Hum Reprod. 2000 Jul;15(7):1431-4. doi: 10.1093/humrep/15.7.1431.
Zotero 插件